Library
of Slides and Posters
•
Therapy for Treatment-experienced Patients
•
Therapy for Treatment-naïve HIV Patients
•
NNRTI-based Regimens
•
Boosted PIs
•
Experimental Antiretrovirals
•
HIV- and antiretroviral-related Adverse Events
•
HIV-related Neurocognitive Impairment and CNS Issues
• Resistance
•
Dosing / Adherence
•
Pharmacokinetics and Drug Interactions
•
Health-related Quality of Life
•
Women and Children
•
HIV/HCV Coinfection and HIV/HBV Coinfection |
 Therapy
for Treatment-experienced Patients
Virologic Suppression Is Maintained After Virologic Suppression Is Maintained After Change To Efavirenz/Emtricitabine/Tenofovir Change To Efavirenz/Emtricitabine/Tenofovir Disoproxil
Fumarate Single Tablet Regimen Disoproxil
Fumarate Single Tablet Regimen (EFV/FTC/TDF) vs. Continuation
of Current (EFV/FTC/TDF) vs. Continuation of Current Antiretroviral Therapy: Study
073 Antiretroviral Therapy: Study 073 -Results of Results of 24 24-week Interim
Efficacy Analyses week Interim Efficacy Analyses
DeJesus
and others.
Pooled
24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine;
ETR) in treatment-experienced HIV-1-infected patients
C Katlama
and others.
Impact
of baseline NNRTI mutations on the virological response
to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2
Phase III clinical trials
B Vingerhoets and
others.
Impact
of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining illnesses
and deaths): 24-week findings from a planned pooled analysis of the DUET studies
J Gatell and others.
Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir
in the TITAN Study
D Sekar and others.
Efficacy
of darunavir/ritonavir in treatment-experienced HIV-1-infected
patients at 96 weeks in the POWER 1 and 2 trials
A Pozniak
and others. Lower virological failure (VF) rate and mutations development during
treatment with darunavir/ritonavir (DRV/r) compared
with lopinavir/ritonavir (LPV/r) in treatment-experienced
patients: TITAN 48-week resistance analysis
S De Meyer and others.
Safety and
tolerability of darunavir/ritonavir in treatment-experienced
HIV-1-infected patients at 96 weeks in the POWER 1, 2 and 3 trials
P
Yeni and others.
Efficacy
analysis of darunavir/r in treatment-experienced POWER
3 patients at Week 96
K Aastéh and others. Analysis of
the cost of full virological suppression for highly
treatment-experienced, HIV-infected patients in the POWER trials in different
European healthcare settings
A Hill and others. Effect of
baseline factors on virological response to darunavir/r and lopinavir/r at Week
48 in TITAN
D Berger and others. Cost-effectiveness
of DRV/r in highly treatment-experienced HIV/AIDS patients in different European
healthcare settings
K Moeremans and others.
ARTEMIS:
Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naïve
patients
N Clumeck
and others.
Linear
modeling to estimate the contribution of each drug component of the regimens of
highly treatment-experienced patients in RESIST
D Hall and others. |
Therapy
for Treatment-naïve HIV Patients
Similar
Virologic Efficacy of Fosamprenavir
+ Ritonavir (FPV/r) Versus Lopinavir/Ritonavir
(LPV/r) Across VL and CD4 Subgroups Over 96 Weeks
C Barros
and others. Copyright GlaxoSmithKline. Used with permission, 2007.
The
Effect of Outcome Uncertainty on Treatment Choices among ART-Naïve HIV-Positive
African Americans (AAs)
A. Hauber
and others. Copyright GlaxoSmithKline. Used with permission, 2007.
TMC278,
a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral
(ARV)-naïve patients: Week 48 primary analysis of study TMC278-C204
P
Yeni and others. |
NNRTI-based
Regimens
Virologic Suppression Is Maintained After Virologic Suppression Is Maintained After Change To Efavirenz/Emtricitabine/Tenofovir Change To Efavirenz/Emtricitabine/Tenofovir Disoproxil
Fumarate Single Tablet Regimen Disoproxil
Fumarate Single Tablet Regimen (EFV/FTC/TDF) vs. Continuation
of Current (EFV/FTC/TDF) vs. Continuation of Current Antiretroviral Therapy: Study
073 Antiretroviral Therapy: Study 073 -Results of Results of 24 24-week Interim
Efficacy Analyses week Interim Efficacy Analyses
DeJesus
and others.
Lack
of Pharmacokinetic (PK) Interaction of Tenofovir (TDF) and Emtricitabine (FTC)
on Nevirapine (NVP)
C Davis and others.
Pooled
24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine;
ETR) in treatment-experienced HIV-1-infected patients
C Katlama
and others.
Impact
of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining illnesses
and deaths): 24-week findings from a planned pooled analysis of the DUET studies
J Gatell and others.
Impact
of baseline NNRTI mutations on the virological response
to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2
Phase III clinical trials
B Vingerhoets and
others.
Thorough
QT trial with TMC125 (etravirine; ETR) dosed at 200mg
bid and 400mg qd in HIV-negative volunteers
M Peeters and others.
No
pharmacokinetic interaction between TMC125 (etravirine;
ETR) and paroxetine in HIV-negative volunteers
M Scholler-Gyure and others.
TMC278,
a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral
(ARV)-naïve patients: Week 48 primary analysis of study TMC278-C204
P
Yeni and others.
Lower
lipid levels in antiretroviral (ARV)-naïve patients receiving the investigational
NNRTI TMC278 versus efavirenz (EFV)
A Pozniak
and others.
The
pharmacokinetic (PK) interaction between atorvastatin
(AVS) and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor
(NNRTI), in HIV-negative volunteers
R Van Heeswijk
and others. |
Boosted
PIs
Patients
who responded to tipranavir/r (500/200 mg BID) plus new enfuvirtide (ENF) at Week
16 of RESIST studies maintain superior virologic and immunologic outcomes through
Week 96
G Pierone and others.
Linear
modeling to estimate the contribution of each drug component of the regimens of
highly treatment-experienced patients in RESIST
D Hall and others.
Tipranavir/r
(TPV/r) maintains long term virological suppression – Three year follow-up of
RESIST
C Hicks and others.
Improving
the prediction of virologic response to tipranavir: the development of a tipranavir
weighted score
J Scherer and others.
The
Effect of Tipranavir/Ritonavir (TPV/r) treatment on the steady state Pharmacokinetics
of Bupropion in Healthy Volunteers
T Lavrut and others. [powerpoint format] Genotypic
tipranavir scores as predictors of response
J Schapiro and others. Tipranavir
displays similar in vitro antiviral activity against non-subtype B clinical isolates
of HIV-1 compared with isolates from subtype B
P Bonneau and others.
Hepatic
profile of tipranavir in treatment experienced HIV-1 infected individuals
S
Pol and others.
Lopinavir/Ritonavir (LPV/r) 100/25 mg Tablet Developed for
Pediatric Use: Bioequivalence to the LPV/r 200/50 mg Tablet at a Dose of 400/100
mg and Predicted Dosing Regimens in Children
C Klein and othes.
Similar
Virologic Efficacy of Fosamprenavir
+ Ritonavir (FPV/r) Versus Lopinavir/Ritonavir
(LPV/r) Across VL and CD4 Subgroups Over 96 Weeks
C Barros
and others. Copyright GlaxoSmithKline. Used with permission, 2007.
Once-Daily
Fosamprenavir (FPV) Boosted with Either 100mg or 200mg
of Ritonavir (r) Along with Abacavir
(ABC)/ Lamivudine (3TC): 48 Week Safety and Efficacy
Results from COL100758
C Hicks and others. Copyright GlaxoSmithKline.
Used with permission, 2007.
Efficacy
of darunavir/ritonavir in treatment-experienced HIV-1-infected
patients at 96 weeks in the POWER 1 and 2 trials
A Pozniak
and others. Lower
virological failure (VF) rate and mutations development during
treatment with darunavir/ritonavir (DRV/r) compared
with lopinavir/ritonavir (LPV/r) in treatment-experienced
patients: TITAN 48-week resistance analysis
S De Meyer and others.
Efficacy
analysis of darunavir/r in treatment-experienced POWER
3 patients at Week 96
K Aastéh and others. Analysis
of the cost of full virological suppression for highly
treatment-experienced, HIV-infected patients in the POWER trials in different
European healthcare settings
A Hill and others. Effect
of baseline factors on virological response to darunavir/r and lopinavir/r at Week
48 in TITAN
D Berger and others. Cost-effectiveness
of DRV/r in highly treatment-experienced HIV/AIDS patients in different European
healthcare settings
K Moeremans and others.
ARTEMIS:
Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naïve
patients
N Clumeck
and others.
Effect
of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir
(DRV/r) in HIV-1 patients: results of a randomised,
controlled, Phase III study (TITAN)
V Sekar
and others. |
Experimental
Antiretrovirals
Pooled
24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine;
ETR) in treatment-experienced HIV-1-infected patients
C Katlama
and others.
Impact
of baseline NNRTI mutations on the virological response
to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2
Phase III clinical trials
B Vingerhoets and
others.
Impact
of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining illnesses
and deaths): 24-week findings from a planned pooled analysis of the DUET studies
J Gatell and others.
Thorough
QT trial with TMC125 (etravirine; ETR) dosed at 200mg
bid and 400mg qd in HIV-negative volunteers
M Peeters and others.
No
pharmacokinetic interaction between TMC125 (etravirine;
ETR) and paroxetine in HIV-negative volunteers
M Scholler-Gyure and others.
TMC278,
a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral
(ARV)-naïve patients: Week 48 primary analysis of study TMC278-C204
P
Yeni and others.
The
pharmacokinetic (PK) interaction between atorvastatin
(AVS) and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor
(NNRTI), in HIV-negative volunteers
R Van Heeswijk
and others. |
HIV-
and antiretroviral-related Adverse Events
The
Effect of Outcome Uncertainty on Treatment Choices among ART-Naïve HIV-Positive
African Americans (AAs)
A. Hauber
and others. Copyright GlaxoSmithKline. Used with permission, 2007.
A
Prospective Epidemiological Study to Determine the Prevalence of HLA-B*5701in
French HIV-1 Infected Patients: PEPI Study
J Molina and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
Characteristics
of Abacavir Hypersensitivity Diagnoses According to
HLA-B*5701Status and Subsequent Abacavir Patch Test
Result
E Phillips and others. Copyright GlaxoSmithKline. Used with permission,
2007.
Lower
lipid levels in antiretroviral (ARV)-naïve patients receiving the investigational
NNRTI TMC278 versus efavirenz (EFV)
A Pozniak
and others.
Safety and
tolerability of darunavir/ritonavir in treatment-experienced
HIV-1-infected patients at 96 weeks in the POWER 1, 2 and 3 trials
P
Yeni and others. |
HIV-related
Neurocognitive Impairment and CNS Issues
Low-Level
HIV-1 Viral Load Monitoring in Cerebrospinal Fluid: Possible Correlation to Antiretroviral
Drug Penetration
D McClernon and others. Copyright
GlaxoSmithKline. Used with permission, 2007. |
Resistance
Impact
of baseline NNRTI mutations on the virological response
to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2
Phase III clinical trials
B Vingerhoets and
others. |
Dosing
/ Adherence
Lopinavir/Ritonavir (LPV/r) 100/25 mg Tablet Developed for
Pediatric Use: Bioequivalence to the LPV/r 200/50 mg Tablet at a Dose of 400/100
mg and Predicted Dosing Regimens in Children
C Klein and othes.
Achieving
and Maintaining Undetectable HIV-1 RNA: The Role of Adherence
R Rodel
and others.
Once-Daily
Fosamprenavir (FPV) Boosted with Either 100mg or 200mg
of Ritonavir (r) Along with Abacavir
(ABC)/ Lamivudine (3TC): 48 Week Safety and Efficacy
Results from COL100758
C Hicks and others. Copyright GlaxoSmithKline.
Used with permission, 2007.
Thorough
QT trial with TMC125 (etravirine; ETR) dosed at 200mg
bid and 400mg qd in HIV-negative volunteers
M Peeters and others. |
Pharmacokinetics
and Drug Interactions
Ritonavir Pharmacokinetics
in Subjects 60 Years or Older
C Klein and others.
No
pharmacokinetic interaction between TMC125 (etravirine;
ETR) and paroxetine in HIV-negative volunteers
M Scholler-Gyure and others.
The
pharmacokinetic (PK) interaction between atorvastatin
(AVS) and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor
(NNRTI), in HIV-negative volunteers
R Van Heeswijk
and others.
Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir
in the TITAN Study
D Sekar and others.
Effect of
extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir
(DRV/r) in HIV-1 patients: results of a randomised,
controlled, Phase III study (TITAN)
V Sekar
and others. |
Health-related
Quality of Life
Health-related
quality of life (HRQL) as measured by the Functional Assessment of HIV Infection
(FAHI) questionnaire in treatment-experienced HIV-1-infected patients: 24-week
results from the pooled DUET trials
K Peeters
and others. |
Women
and Children
Lopinavir/Ritonavir (LPV/r) 100/25 mg Tablet Developed for
Pediatric Use: Bioequivalence to the LPV/r 200/50 mg Tablet at a Dose of 400/100
mg and Predicted Dosing Regimens in Children
C Klein and othes. |
HIV/HCV
Coinfection and HIV/HBV Coinfection
Tolerability
of darunavir/r versus lopinavir/r
in lopinavir/r-naïve, treatment-experienced, hepatitis
B and/or C co-infected
D
Bánhegyi nd others. Tipranavir
Patients
who responded to tipranavir/r (500/200 mg BID) plus new enfuvirtide (ENF) at Week
16 of RESIST studies maintain superior virologic and immunologic outcomes through
Week 96
G Pierone and others.
Tipranavir/r
(TPV/r) maintains long term virological suppression – Three year follow-up of
RESIST
C Hicks and others.
Improving
the prediction of virologic response to tipranavir: the development of a tipranavir
weighted score
J Scherer and others. The
Effect of Tipranavir/Ritonavir (TPV/r) treatment on the steady state Pharmacokinetics
of Bupropion in Healthy Volunteers
T Lavrut and others. [powerpoint format] Genotypic
tipranavir scores as predictors of response
J Schapiro and others.
Linear
modeling to estimate the contribution of each drug component of the regimens of
highly treatment-experienced patients in RESIST
D Hall and others.
Lack
of Pharmacokinetic (PK) Interaction of Tenofovir (TDF) and Emtricitabine (FTC)
on Nevirapine (NVP)
C Davis and others.
Hepatic
profile of tipranavir in treatment experienced HIV-1 infected individuals
S
Pol and others.
Tipranavir
displays similar in vitro antiviral activity against non-subtype B clinical isolates
of HIV-1 compared with isolates from subtype B
P Bonneau and others.
|
